Search
Search Results
-
MFN2 Protein Regulates Cisplatin Sensitivity in Non-Small Cell Lung Cancer by Regulating Mitochondrial Autophagy
This work was aimed to explore the mechanism of Mfn2 protein dependent cisplatin sensitivity in non-small cell lung cancer (NSCLC) by regulating...
-
Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
BackgroundLung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the...
-
Anti-angiogenesis revisited: resha** the treatment landscape of advanced non-small cell lung cancer
Although anti-angiogenic agents have been of limited use in the treatment of non-small cell lung cancer (NSCLC) until recently, further roles for the...
-
CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell–mediated cytotoxicity
The susceptibility of cancer cells to natural killer (NK) cell–mediated cytotoxicity depends on the balance of activating and inhibitory ligands...
-
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
Pralsetinib (PRL) is a selective Rearranged during Transfection (RET) inhibitor, developed by Blueprint Medicines Corporation for the treatment of...
-
Mechanisms of resistance to chemotherapy in non-small cell lung cancer
Non-small cell lung cancer (NSCLC), which represents 80–85% of lung cancer cases, is one of the leading causes of human death worldwide. The majority...
-
Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC
Gefitinib, as the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has achieved great advances in the...
-
A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I–IIIB Non-small Cell Lung Cancer
ObjectiveThe status of lymph node metastasis (LNM) is highly correlated with the recurrence and survival outcomes of patients with lung cancer. Thus,...
-
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer
In this article, we focus on the reimbursement process, and as an example, characterize the time to reimbursement of pembrolizumab , a PD-1 immune...
-
Synthesis of Myrtucommulone D: A Selective Inhibitor of Tyrosyl-DNA Phosphodiesterase 2 Promoting Drug Resistance Reversal in Lung Cancer Cells
Chemoresistance has emerged as a critical barrier in the treatment of lung cancer. The recently discovered DNA repair enzyme, tyrosyl-DNA...
-
Anti-lung Cancer Marine Compounds: A Review
Lung cancer is one of the most common and lethal cancers in human beings. Lung cancer has been divided into two major types: small cell lung cancer...
-
Mahanimbine Suppresses the Proliferation of Lung Cancer A549 Cells Via Inducing Intrinsic Apoptotic Pathway
Mahanimbine is a carbazole alkaloid that has been identified and isolated from several members of the Rutaceae family. Previous studies have...
-
Pharmacogenomics and Cancer Treatment
Somatic and germline genetic variations are two types of interindividual variations affecting drug response in cancer treatment. Pharmacogenomics...
-
Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy
Natural compounds originating from plants offer a wide range of pharmacological potential and have traditionally been used to treat a wide range of...
-
Design and optimization various formulations of PEGylated niosomal nanoparticles loaded with phytochemical agents: potential anti-cancer effects against human lung cancer cells
BackgroundPhytochemicals and their derivatives are good options to improve treatment efficiency in cancer patients. Artemisinin (ART) and metformin...
-
Characteristics of Drug Intervention Clinical Trials and Scientific Impact of the Trial Outcome: A Bibliometric Analysis Using the Relative Citation Ratio in Non-small Cell Lung Cancer from 2007 to 2016
BackgroundAlthough a large number of clinical trials have been conducted, the types of clinical trials that are scientifically influential,...
-
PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: Involvement of ROS and mitophagy
BackgroundDespite significant strides in understanding the pathophysiology of non-small cell lung cancer (NSCLC), these neoplasms typically present...
-
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key...
-
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By...
-
Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
BackgroundThe epidermal growth factor receptor (EGFR) inhibitors represent the first-line therapy regimen for non-small cell lung cancer (NSCLC)....
